The mobilization of metabolic energy from adipocytes depends on a tightly regulated balance between hydrolysis and resynthesis of triacylglycerides (TAGs). Hydrolysis is stimulated by b-adrenergic signalling to PKA that mediates phosphorylation of lipolytic enzymes, including hormonesensitive lipase (HSL). TAG resynthesis is associated with high-energy consumption, which when inordinate, leads to increased AMPK activity that acts to restrain hydrolysis of TAGs by inhibiting PKA-mediated activation of HSL. Here, we report that in primary mouse adipocytes, PKA associates with and phosphorylates AMPKa1 at Ser-173 to impede threonine (Thr-172) phosphorylation and thus activation of AMPKa1 by LKB1 in response to lipolytic signals. Activation of AMPKa1 by LKB1 is also blocked by PKA-mediated phosphorylation of AMPKa1 in vitro. Functional analysis of an AMPKa1 species carrying a non-phosphorylatable mutation at Ser-173 revealed a critical function of this phosphorylation for efficient release of free fatty acids and glycerol in response to PKAactivating signals. These results suggest a new mechanism of negative regulation of AMPK activity by PKA that is important for converting a lipolytic signal into an effective lipolytic response.
Introduction
White adipocytes have a central function in the control of whole-body energy homeostasis (Rosen and Spiegelman, 2006) . These cells are able to accumulate and store dietary energy in the form of triacylglycerides (TAGs) through lipid synthesis and to mobilize the stored energy in times of caloric need by hydrolysing TAGs to generate non-esterified free fatty acids (NEFAs) and glycerol that are released into the circulation for use by other organs as energy substrates (Duncan et al, 2007) . A breakdown in the regulation of adipocyte lipid storage and mobilization pathways can contribute to increased levels of NEFA in the circulation, which is an established risk factor for the development of insulin resistance in type II diabetes and related disorders (Gesta et al, 2006; Guilherme et al, 2008) .
In the basal state, the TAG pool in adipocytes is in a constant state of flux in that NEFAs are continuously released from TAG stores and reesterified again to produce TAG (Duncan et al, 2007) . The simultaneously ongoing breakdown or lipolysis and resynthesis of TAG creates a 'substrate cycle' referred to as the TAG-NEFA cycle, which is characterized by energy expenditure in the absence of net conversion of substrate into product and allows adipocytes to respond rapidly to changes in peripheral requirements of NEFA (Kalderon et al, 2000; Large et al, 2004) . Indeed, during periods of increased energy demands, the rate of lipolysis is enhanced through the action of lipolytic hormones that stimulate b-adrenergic signalling to activate the cAMP-PKA pathway (McKnight et al, 1998) , which mediates phosphorylation and activation of lipolytic enzymes, including perilipin, adipose triglyceride lipase and hormone-sensitive lipase (HSL) (Khoo et al, 1972; Holm, 2003; Schweiger et al, 2006; Ducharme and Bickel, 2008; Granneman and Moore, 2008; Zimmermann et al, 2009) .
Phosphorylation of HSL occurs on multiple sites, including Ser-660, which stimulates catalytic activity and Ser-563, which is believed to be mutually exclusive with phosphorylation of HSL at the non-PKA site Ser-565 (Anthonsen et al, 1998; Watt et al, 2006) . Thus, hormonal cues that signal systemic energy induce HSL phosphorylation at Ser-563 by PKA, which contributes to adipocyte lipolysis to maintain whole-body energy homeostasis.
Existing evidence suggests that even during fasting as much as 30-40% of NEFAs released from TAG stores are reesterified (Reshef et al, 2003) , providing a mechanism to limit NEFA release into the circulation. The reesterification step of the TAG-NEFA cycle is a highly energy-demanding process that consumes significant amounts of cellular ATP and also generates AMP, and when immoderate, can create a state of relative energy depletion (Gauthier et al, 2008) . A key sensor of cellular energy level is AMPK (Hardie et al, 2006; Hue and Rider, 2007; Hardie, 2008) , a heterotrimeric kinase complex, composed of the catalytic kinase a subunit and two associated regulatory subunits, b and g, that maintains the balance between ATP production and consumption. AMPK is activated by phosphorylation of the critical activation loop threonine in the a-subunit that is mediated by upstream kinases (Carling et al, 2008) . Prominent among these is the tumour suppressor kinase LKB1 (Sakamoto et al, 2005; Shaw et al, 2005) . Energy stress leads to an increase in the AMP:ATP ratio and AMP binds directly to the AMPKg subunit, thereby stimulating the kinase activity allosterically and inducing a conformational change that inhibits the deactivation by phosphatases (Suter et al, 2006; Sanders et al, 2007) . In the context of adipocytes, evidence suggests that AMPK is activated as a consequence of constitutively ongoing reesterification that consumes energy (Gauthier et al, 2008 ). An immediate consequence of enhanced AMPK activity is the phosphorylation of HSL at Ser-565, which precludes activation of HSL by PKA (Garton et al, 1989; Daval et al, 2005) . Thus, stimulation of adipocyte lipolysis through PKA activation triggers, in turn, a negative feedback mechanism involving AMPK to match the rate of lipolysis to energy supply. The mechanism(s) underlying coordination of these apparently opposing activities under conditions of acute systemic metabolic needs remain elusive. Hence, we explored whether PKA and AMPK kinase pathways crosstalk in adipocytes as part of their lipolysis regulatory functions.
Results

PKA and AMPK associate in vivo
Primary mouse adipocytes were treated with isoproterenol, an epinephrine analogue and b-adrenergic agonist that simulates the physiological stimulus for lipolysis during fasting, to activate the cAMP-PKA pathway. The activation state of AMPK was monitored using an antibody specific for AMPKa that is phosphorylated on Thr-172, the critical residue in the activation loop of AMPKa phosphorylated by LKB1 (Hawley et al, 1996) . As shown in Figure 1A , 30 min of 200 nM isoproterenol treatment suppressed basal AMPKa phosphorylation at Thr-172 (compare lanes 2 and 1). Simultaneous addition of 1 mM H89, a pharmacological inhibitor of PKA, prevented this (lane 3). The effect of PKA signalling on Thr-172 phosphorylation of AMPKa under AMPK-activating conditions, such as in response to glucose deprivation or addition of 1 mM of the AMP-mimicking agent aminoimidazole carboxamide ribonucleotide (AICAR), was also evaluated. As expected, these treatments induced AMPKa Thr-172 and Ser-79 AMPK substrate acetyl-CoAcarboxylase (ACC) phosphorylation (compare lanes 4, 7 and 1). Induction of AMPKa phosphorylation was, however, blocked by isoproterenol (lanes 5 and 8) and recovered in the presence of H89 inhibitor (lanes 6 and 9). Thus, signals that activate PKA reduce AMPKa phosphorylation at Thr-172. In line with these data, isoproterenol inhibits AMPK activity as assessed by the ability of AMPKa1 immunoprecipitates to phosphorylate SAMS peptide (Supplementary Figure S1A) . Consistent with this finding, the phosphorylation state of an established common effector of PKA and AMPK in the regulation of lipolysis, HSL, changed accordingly. Conditions that activated PKA-induced phosphorylation of HSL at Ser-660 and Ser-563 and suppressed phosphorylation of HSL at the AMPK site Ser-565 ( Figure 1A) . Conversely, inhibition of PKA signalling reversed these effects, resulting in increased phosphorylation of HSL at the AMPK site Ser-565 ( Figure 1A ). Similar changes in the phosphorylation states of AMPKa, ACC and HSL were observed when PKA signalling was induced by 20 mM forskolin, a potent inhibitor of phosphodiesterases that leads to cAMP increase, or suppressed by 100 mM of a specific myristoylated protein kinase A inhibitor (PKi) ( Figure 1B ). Activation of Ca 2 þ signalling by ionomycin did not interfere with Thr-172 phosphorylation of AMPKa in adipocytes (Supplementary Figure S1B) . The negative effect of forskolin on AMPK Thr-172 phosphorylation was first detectable around 20 min after treatment ( Figure 1C ) and correlated with increased phosphorylation of HSL at Ser-660 and the cAMP response element-binding protein (CREB) at Ser-133 (both PKA mediated) and decreased phosphorylation of ACC at Ser-79 and HSL at Ser-565 (both AMPK mediated) ( Figure 1C ). In vitro kinase assays using purified PKA and AMPK further support the notion that phosphorylation of HSL at Ser-563 and Ser-565 is mutually exclusive. Specifically, phosphorylation of purified glutathione-S-transferase (GST)-HSL fusion protein at Ser-563 by PKA renders the substrate resistant to subsequent phosphorylation at Ser-565 by AMPK complexes in which the Thr-172 residue of the AMPKa1 subunit has been mutated to an aspartic acid, referred to as AMPK(T172D) to yield constitutive active kinase complexes ( Figure 1D ). In contrast, when GST-HSL was first phosphorylated by AMPK(T172D), PKA failed to phosphorylate HSL at Ser-563 ( Figure 1D ). In keeping with these observed changes in the phosphorylation state of HSL, isoproterenol-stimulated NEFA release from adipocytes, whereas addition of H89 inhibitor blocked both basal and isoproterenol-induced NEFA release ( Figure 1E ), whereas glucose deprivation or treatment of cells with AICAR that activates AMPK caused reduced basal and isoproterenolinduced NEFAs release ( Figure 1E ). As phosphorylation of AMPK at Thr-172 is required for kinase activation, these findings imply that activation of PKA in adipocytes suppresses, directly or indirectly, AMPK activity and thus the extend to which the downstream effector of PKA, HSL, is phosphorylated. Finally, we detected PKAa in endogenous AMPKa1 immunoprecipitates derived from primary adipocytes whole-cell extracts ( Figure 1F , lane 3), suggesting that PKAa and AMPKa1 physically interact in vivo. Stable complex formation of these kinases was, however, not affected by treatment of cells with either isoproterenol or ionomycin (Supplementary Figure S1C) .
PKA phosphorylates AMPKa1 at Ser-173, Ser-485, Ser-497 and AMPKb1 at Ser-24 Given the observation that PKA signalling inhibits AMPK activation and that these two kinases associate in vivo, we asked next whether PKA phosphorylates AMPK in vitro. For these assays, we produced heterotrimeric AMPK complexes with a catalytically inactive AMPKa1 subunit in which Asp-157 has been mutated to alanine in bacteria. We refer to this complex as AMPK(D157A). It follows that incorporation of radioactive phosphate into any of the AMPK subunits would then be solely due to the action of PKA and not due to autophosphorylation activity of AMPK. Indeed, the constitutively active catalytic subunit of PKA (PKA[cat]) or a partially purified PKA holoenzyme (PKA[holo] ) that is dependent on cAMP for full activity, both phosphorylated the catalytic a1-and regulatory b1-subunits of AMPK(D157A) Figure 2A) . Phosphorylation of the AMPKg1 subunit by PKA was not observed under these conditions. Conversely, PKAa did not serve as a substrate for active AMPK in vitro (data not shown). Phosphorylation site mapping by mass spectrometry and solid-phase sequencing revealed that PKA phosphorylated the AMPKa1 subunit at Ser-173, Ser-485 and Ser-497 and the b1-subunit at Ser-24 ( Figure 2B and C, respectively). All these sites are highly conserved between human, mouse and rat AMPK subunits (Supplementary Figure S2) . In addition, the amino-acid sequence encompassing the Ser-173 site in AMPKa1 is also conserved in rat AMPKa2 (Supplementary Figure S2A) . It has been reported that a1-containing AMPK is the predominant complex in adipocytes accounting for 490% of total AMPK activity detectable in these cells (Lihn et al, 2004; Daval et al, 2005) . Therefore, we focused our further analysis on the regulation of AMPKa1 by PKA. Mutation of each of the above-noted serine residues to alanine as well as combined mutations of these critical serines were introduced as secondary mutations in AMPKa1(D157A)-or b1-subunits and the corresponding AMPK complexes exposed to PKA. Only complexes harbouring the triple mutant of AMPKa1(S173A/S485/S497A) ( Figure 2D ) or the single mutant AMPKb1(S24A) ( Figure 2E ) proved to be resistant to PKA phosphorylation, suggesting that each of these sites can be phosphorylated by PKA in vitro.
Phosphorylation of AMPKa1 at Ser-173 by PKA precludes phosphorylation of AMPKa1 at Thr-172 by LKB1 Next, we assessed whether phosphorylation of AMPKa1 by either LKB1 or PKA interferes with subsequent phosphorylation by PKA and LKB1, respectively. As shown above, PKA phosphorylates AMPK(D157A/S485A/S497A) complexes at Ser-173 as AMPK(D157A/S485A/S497A/S173A) complexes that harbour an additional mutation at Ser-173 are resistant to phosphorylation by this kinase (see Figure 2D , compare lanes 7 and 8). Consistent with these data, PKA phosphorylated AMPKa1(D157A/S485A/S497A) at Ser-173 as evidenced by 32 P-incorporation and recognition by antiphospho Ser-173 antibodies ( Figure 3A , lane 3). When AMPK(D157A/S485A/S497A) complexes were incubated with LKB1 before the addition of PKA, phosphorylation of AMPKa1(D157A/S485A/S497A) by PKA still occurred to a similar extend as indicated by 32 P-incorporation ( Figure 3A, lane 4) . However, the anti-phospho Ser-173 antibodies failed now to recognize the phospho-Ser173 epitope ( Figure 3A, In reciprocal experiments, LKB1 phosphorylated AMPK (D157A) complexes on Thr-172 as evidenced by 32 P-incorporation and recognition of AMPKa1(D157A) by anti-phospho Thr-172 antibodies ( Figure 3B , lane 2). Importantly, when AMPK(D157A) complexes were incubated with PKA before the addition of LKB1, Ser-173 phosphorylation occurred but autoradiography of in vitro kinase assays show that subsequent phosphorylation of AMPKa1(D157A) at Thr-172 by LKB1 was blocked ( Figure 3B , lane 4). Phosphorylation of AMPKa1(D157A) by LKB1 at Thr-172 was, however, observed when PKA was inhibited by PKA inhibitory peptide PKi ( Figure 3B , lane 3). Addition of PKi alone did not negatively affect LKB1-mediated AMPKa1(D157A) phosphorylation at Thr-172 in the absence of PKA ( Figure 3B , lane 1). These results suggest that PKA-mediated phosphorylation of AMPKa1 at Ser-173 interferes with subsequent LKB1 phosphorylation of AMPKa1 at Thr-172.
Accordingly, LKB1-mediated activation of AMPK, as measured by the ability of AMPK to phosphorylate the synthetic peptide substrate SAMS, decreased, as increasing amounts of PKA were added to the reaction mix ( Figure 3C ). The observed decline in AMPK activity correlated with a decrease in Thr-172 phosphorylation and an increase in Ser-173 phosphorylation of AMPKa1 ( Figure 3D ). Moreover, when PKAphosphorylated AMPK was treated with l phosphatase before the addition of LKB1, activation of AMPK was recovered ( Figure 3E ). Immunoblotting revealed that l phosphatase caused dephosphorylation of AMPKa1 at Ser-173 and that LKB1 phosphorylated AMPKa1 at the adjacent Thr-172
AMPK ( Figure 3F ). These results suggest that PKA phosphorylation of AMPKa1 prohibits subsequent activation of AMPK by LKB1 at Thr-172.
Ser-173 phosphorylation of AMPKa1 antagonizes phosphorylation of AMPKa1 at Thr-172 by LKB1
To elucidate the molecular mechanism underlying PKAmediated inhibition of AMPK activation by LKB1, we generated a non-phosphorylatable mutant of AMPKa1 in which Ser-173 was mutated to an alanine residue. The AMPKa1(S173A) mutant protein proved to be resistant to Thr-172 phosphorylation by LKB1, but was still phosphorylated at Ser-485 and Ser-497 by PKA ( Figure 4A ). One possible explanation of a failure of LKB1 to phosphorylate Thr-172 in AMPKa1 in the context of a Ser-173 to alanine mutation may relate to the fact that these two sites are located within the recognition sequence of LKB1. Alternatively, the mutation may disrupt the epitope of the phospho-Thr-172
antibody. However, we also failed to observe any 32 P-incorporation into the AMPKa1(S173A) mutant protein on exposure to LKB1 ( Figure 4A ). Therefore, it is likely that the introduction of an alanine residue at Ser-173 affects the ability of LKB1 to phosphorylate Thr-172. We note that equivalent alanine mutations of AMPKa1 at Ser-485 and/or Ser-497 ( Figure 4B ) or AMPKb1 at Ser-24 (Supplementary Figure S3) did not negatively affect Thr-172 phosphorylation of AMPKa1 by LKB1. Furthermore, the ability of PKA to inhibit subsequent activation by LKB1 was preserved in AMPKa1(S485A), AMPKa1(S497A) and AMPKb1(S24A) mutant complexes, thus suggesting that these sites are not responsible for PKA-mediated inhibition.
Given these findings, we hypothesized that phosphorylation of Ser-173 in AMPKa1 may be critical to PKA-dependent inhibition of AMPK activation. Thus, we endeavored to construct a phosphorylation site mutant capable of phosphorylation by LKB1. We replaced the hydroxyl group of Ser-173 4) . Phosphorylation of Thr-172 and Ser-173 is coexistent, if PKA is allowed to phosphorylate AMPK after preincubation with LKB1 (lane 4). In this double-phosphorylated form, phosphorylation of Thr-172 but not Ser-173 was recognized by the corresponding antibodies. PKi, PKA inhibitor. Samples were processed for immunoblotting with the specified antibodies. (B) PKA phosphorylation of AMPKa1 prevents LKB1-mediated Thr-172 phosphorylation in vitro. AMPKa1(D157A) was preincubated with/without PKA and non-radioactive ATP as indicated, followed by LKB1 assays in the presence of [g-32 P]ATP. LKB1 was unable to phosphorylate AMPK after PKA phosphorylation. Samples were processed for immunoblotting with the specified antibodies. (C) PKA-mediated AMPKa1 phosphorylation inhibits AMPK activity. AMPK was preincubated with different amounts of PKA before in vitro kinase reactions with LKB1. AMPK activity assessed as the amount of phosphate incorporated into the synthetic peptide substrate SAMS. (D) Immunoblot corresponding to (B) probed with the indicated antibodies. (E) PKAphosphorylated AMPK was either left untreated or dephosphorylated with l-PPase using the indicated concentrations, then processed for in vitro kinase assays with or without LKB1. AMPK activity quantified using the SAMS assay. (F) Immunoblot corresponding to (E) probed with the indicated antibodies. All activity measurements were done in triplicates. Error bars represent ± s.e.m. Immunoblots are representative of at least three independent experiments.
in AMPKa1 more conservatively with a thiol group by mutating the serine to a cysteine residue, thereby maintaining the nucleophilic nature and approximative size of the side chain. As shown in Figure 4C , AMPKa1(D157A) and AMPKa1(D157A/S173C) mutant proteins were readily phosphorylated at Thr-172 by LKB1 as evidenced by autoradiography of in vitro kinase assays (upper panel) and immunoblotting with a phospho-specific antibody (lower panel). When coexpressed with b-and g-subunits in bacteria, the AMPKa1(S173C) single mutant also assembled as efficient as AMPKa1 wild type into trimeric AMPK complexes ( Figure 4D ). Importantly, however, LKB1 phosphorylated the AMPKa1(D157A/S173C) mutant at Thr-172 despite preincubation of the AMPK(D157A/S173C) complex with PKA ( Figure 4E, lane 5) . Notably, in this setting, PKA was active and phosphorylated Ser-485 and Ser-497 in AMPKa1(D157A/ S173C) ( Figure 4E ). These results strongly suggest that phosphorylation of AMPKa1 at Ser-173 by PKA renders AMPKa1 refractory to the subsequent activating phosphorylation at Thr-172 by LKB1.
PKA-mediated phosphorylation of AMPKa1 at Ser-173 efficiently interferes with LKB1-dependent AMPK activation
To further assess the functional significance of Ser-173 phosphorylation, we next measured the inhibitory effect of PKA on activation of AMPK or AMPK(S173C) by LKB1. To this end, highly phosphorylated AMPK or AMPK(S173C) complexes were produced by coexpression with PKA in bacteria. After purification, the corresponding AMPK complexes were dephosphorylated with varying amounts of l phosphatase and subsequently incubated with LKB1. AMPK activity was determined using the synthetic peptide substrate SAMS. As shown in Figure 5A , although activation of AMPK by LKB1 was dependent on prior dephosphorylation with l phosphatase, activation of AMPK(S173C) was not. Immunoblotting with phospho-specific antibodies confirmed that the AMPKa1 wild type had been dephosphorylated on Ser-173 and that both AMPKa1 wild type and the Ser-173A mutant protein were subsequently phosphorylated by LKB1 at Thr-172 ( Figure 5B and C). The AMPK(S173C) complexes phosphorylated HSL at Note that LKB1 is unable to phosphorylate this mutant AMPK protein, suggesting that Ser-173 is a key residue in the recognition sequence for LKB1. As control, AMPK(wt) was used in the assay (lane 1). (B) Mutation of Ser-485 and/or Ser-497 on AMPKa1 does not abolish the inhibitory effect of PKA. AMPK mutants were incubated with PKA and LKB1. Reactions were performed in the absence or presence of PKi as indicated. In vitro kinase assays were processed for immunoblotting with the indicated antibodies. Neither mutation of Ser-485 nor Ser-497 was able to nullify the inhibitory action of PKA on LKB1-mediated Thr-172 phosphorylation (lanes 7-15). Note that no phosphorylation of Thr-172 by LKB1 was observed when Ser-173 was exchanged to alanine (lanes 4-6). (C) AMPK(D157A) (lanes 1-3) and AMPK(D157A/S173C) (lanes 4-6) complexes were either incubated with LKB1 or not, in the presence of [g-32 P]ATP. AMPKa1(D157A) and AMPKa1(D157A/S173C) protein phosphorylation assessed by autoradiography (upper panel) and immunoblotting (lower panel). (D) AMPK(S173C) forms a 1:1:1 complex with the regulatory b-and g-subunits in vitro. Histidine-tagged wild-type AMPKa1 or the (S173C) mutant thereof were coexpressed with the AMPK b-and g-subunits, followed by affinity chromatography with Ni 2 þ -NTA, SDS-PAGE and Coomassie blue staining. (E) AMPK(D157A/S173C) complexes were incubated with or without PKA and then treated with LKB1. Reactions were performed in the absence or presence of PKi as indicated. In vitro kinase assays were processed for immunoblotting with the indicated antibodies. Immunoblots are representative of at least three independent experiments. the established Ser-565 site only on activation by LKB1 ( Figure 5D ), thus confirming the functional integrity of the mutant enzyme. In further support of this notion, both proteins, when individually expressed as myc-tagged species in primary adipocytes using recombinant adenoviruses, formed complexes with endogenous AMPKb1 and g1 subunits as well as with PKA as shown by coimmunoprecipitation assays (Supplementary Figure S4) . Taken together, these results suggest that phosphorylation of AMPKa1 at Ser-173 by PKA efficiently interferes with LKB1-dependent Thr-172 phosphorylation and activation of AMPK, thus providing a mechanistic explanation for the observed suppression of AMPK activation in response to cAMP-elevating agents.
PKA-mediated phosphorylation of AMPKa at Ser-173 is critical for efficient lipolysis
Next, we asked whether forskolin stimulation of glucosedeprived adipocytes induces phosphorylation of AMPKa at Ser-173 in vivo and if so, whether this correlates with a lack of HSL phosphorylation at the AMPK site Ser-565. Stimulation of PKA by forskolin induced downregulation of Thr-172 phosphorylation, upregulation of Ser-173 phosphorylation and a concomitant decrease in HSL phosphorylation on the AMPK site Ser-565 ( Figure 6A ). As expected, the phosphorylation of ACC at residue Ser-79 correlated with the level of AMPKa Thr-172 and HSL Ser-565 phosphorylation ( Figure 6A) . A myristoylated PKi peptide, when added to adipocytes, reversed the negative effect of forskolin on Thr-172 phosphorylation of AMPKa, indicating that this event is PKA dependent ( Figure 6A ). Consistent with the observed changes in kinase and substrate phosphorylation states, 20 mM forskolin-stimulated NEFA release in glucose-deprived adipocytes ( Figure 6B ). Addition of 100 mM of PKi inhibitor blocked both basal and forskolin-induced NEFA release from adipocytes ( Figure 6B ). These data suggest that Ser-173 is a bona fide phosphorylation site of AMPKa in vivo and that activation of PKA by forskolin increases phosphorylation of AMPKa at Ser-173. Importantly, this regulatory mechanism is not restricted to adipocytes alone but extends also to other cell types. First, 20 mM forskolin treatment inhibits glucose starvation-induced Thr-172 phosphorylation of AMPKa in U2-OS osteosarcoma and HepG2 hepatoma cells, while promoting AMPKa Ser-173 phosphorylation in a time-dependent manner (Supplementary Figure S5A and B, respectively). Moreover, in U2-OS cells, glucose starvation-induced Thr-172 phosphorylation of AMPKa is significantly enhanced in U2-OS cells depleted for both PKAa and b subunits (Supplementary Figure S5C) . Finally, endogenous AMPKa1 immunoprecipitates derived from U2-OS cells also contain PKAa (Supplementary Figure S5D) .
We next sought to determine the functional consequences of PKA-mediated inhibition of AMPK activation by LKB1 on lipolysis. Differentiation of mouse embryo fibroblasts (MEFs) into adipocytes by hormonal induction is a well-established model system for the study of adipogenesis and the regulation of lipolysis (Tanaka et al, 1997) . Therefore, we isolated MEFs from AMPKa1À/À and AMPKa2lox/lox mice (Vaahtomeri et al, 2008) , immortalized these cells by stably expressing a mutant p53 allele and infected with adenovirus encoding Cre recombinase to obtain AMPKa null cells (referred thereafter as AMPKaÀ/À cells). MEFs harbouring still one allele of AMPKa1 and AMPKa2 served as control (referred thereafter to as AMPKa þ /À cells). When AMPKa þ /À MEFs infected with control adenoviruses expressing green fluorescence protein only were exposed to differentiation medium to induce adipogenesis, we observed efficient lipid accumulation in differentiated cells as indicated by Oil Red-O staining (Supplementary Figure S6A, E and I) . Figure 6C ). The observed changes in the phosphorylation state of myc-AMPKa1(wt) were particularly pronounced on glucose starvation. Importantly, isoproterenol failed to suppress Thr-172 phosphorylation in cells expressing the myc-AMPKa1(S173C) mutant, suggesting that phosphorylation of AMPKa1 at Ser-173 is inhibitory to Thr-172 phosphorylation. Immunoblotting also revealed that both myc-AMPKa1(wt) and myc-AMPKa1(S173C) mutant are produced at similar amounts ( Figure 6C) . Furthermore, the failure of isoproterenol to suppress phosphorylation of myc-AMPKa1(S173C) at Thr-172 translated into a failure to induce phosphorylation of HSL at Ser-660 (a PKA site) and to suppress phosphorylation of HSL at Ser-565 (an AMPK site) ( Figure 6C ). As a consequence, we observed significant less release of glycerol from myc-AMPKa1(S173C) expressing adipocytes as compared with adipocytes expressing myc-AMPKa1(wt) ( Figure 6D ). These results suggest that PKA-mediated phosphorylation of AMPKa1 at Ser-173 is critical for efficient lipolysis in vivo.
Long-term isoproterenol treatment induces phosphorylation of AMPKa1 at Thr-172 and activates AMPKa1
Recently, it has been proposed that AMPK is activated during lipolysis because of the high energy demand of resynthesis of TAG (Gauthier et al, 2008; Omar et al, 2009 ), a pathway which becomes activated as a consequence of PKA-mediated stimulation of NEFA release. Thus, we asked whether extended treatment of primary adipocytes with isoproterenol 3) and then treated with 20 mM forskolin (FSK) alone (lane 2) or in combination with 100 mM PKi (lane 3). NEFA were measured in the incubation medium. Bars represent the mean NEFA release from three independent experiments. (C) AMPKa1(S173C) is refractory to inhibition by PKA. Immortalized control AMPKa þ /À and AMPKaÀ/À MEFs were differentiated into adipocytes as described in the Materials and methods section. AMPKaÀ/À adipocytes were infected with an adenovirus containing either an empty plasmid (lanes 2, 3, 8, 9), a plasmid encoding for myc-AMPKa1(wt) (lanes 4, 5, 10, 11) or mycAMPKa1(S173C) (lanes 6, 7, 12, 13) . Before immunoblotting experiments and lipolysis assays, adipocytes were grown for 30 min in the presence ( þ Glc) (lanes 2-7) or absence (ÀGlc) (lanes 8-13) of glucose and simultaneously treated with or without 200 nM isoproterenol (Iso). Aliquots of protein lysates were immunoblotted with the indicated antibodies. (D) Incubation medium of adipocytes described in (C) were processed for glycerol measurements. Bars represent the mean of glycerol release from three independent experiments and immunoblots are representative of at least three independent experiments. would engage such a negative feedback mechanism resulting in a decrease in Ser-173 and increase in Thr-172 phosphorylation of AMPKa at later time points. Indeed, measurements of ATP levels confirmed that long-term treatment of primary adipocytes with the lipolytic agent isoproterenol caused a significant decline in ATP levels at later time points (Supplementary Figure S7A) . This was paralleled by an increase in AMPKa Thr-172 phosphorylation and of its activity as assessed by the ability of AMPKa1 immunoprecipitates to phosphorylate SAMS peptide (Supplementary Figure S7B) . Consistent with these findings, there was a concomitant increase in the phosphorylation levels of the AMPK substrates ACC and HSL at Ser-79 and Ser-565, respectively ( Figure 7A, lanes 5-8) . At earlier times after 200 nM isoproterenol treatment, phosphorylation of PKA substrates prevailed as evidenced by high levels of HSL and CREB phosphorylation at Ser-660 and Ser-133, respectively ( Figure 7A, lanes 2-4) . This was also apparent for AMPKa, which became rapidly phosphorylated at Ser-173 during the early time points ( Figure 7A, lanes 2-4) . As the anti-phospho Ser-173 antibodies used here cannot recognize phosphorylated Ser-173 when AMPKa is phosphorylated at Thr-172 (see Figure 3A and B), we cannot formally exclude the possibility that Ser-173 remains phosphorylated despite increased phosphorylation of AMPKa at Thr-172 at later time points. Finally, NEFA release from isoproterenol-stimulated adipocytes increased in parallel to phosphorylation of the PKA substrates investigated and declined when AMPKa became increasingly phosphorylated at Thr-172 ( Figure 7B ). Together, these results suggest that in response to lipolytic signals such as isoproterenol, adipocytes induce, in a first phase, activation of PKA and phosphorylation of HSL and, in a second phase, activation of AMPK, which is accompanied by a decline in NEFA release.
In an effort to further investigate whether phosphorylation of AMPKa at Ser-173 and Thr-172 changes in a manner dependent on stimulated lipolysis, we treated adipocytes with 50 mM orlistat, a pharmacological inhibitor of lipolysis. Importantly, orlistat treatment blocked AMPK activation as evidenced by reduced Thr-172 phosphorylation of AMPKa. Phosphorylation of AMPKa at Ser-173 remained at elevated levels ( Figure 7C ), consistent with reduced Thr-172 phosphorylation of AMPKa. As expected, orlistat inhibited isoproterenol-induced NEFA release ( Figure 7D ). These findings support the view that ongoing lipolysis is important for changes in the antagonistic phosphorylation of AMPKa at Ser-173 and Thr-172 after long-term stimulation of badrenergic signalling. Importantly, when adipocytes were stimulated with isoproterenol in the presence of 10 mM of triacsin C, a potent inhibitor of long chain fatty acyl CoA synthetase that blocks the reesterification of NEFA, AMPKa phosphorylation at Thr-172 was also blunted, whereas phosphorylation of Ser-173 persisted as with orlistat ( Figure 7E ). However, release of NEFA (data not shown) or glycerol ( Figure 7F ) remained elevated even after long-term treatment.
Discussion
Here, we provide direct evidence that PKA phosphorylates AMPKa to antagonize activation of AMPKa by LKB1 and show that this mechanism is critically important for implementing an effective lipolytic response to lipolytic signals conveyed through the cAMP-PKA pathway. Central to this mechanism of crosstalk between a hormone stimulated and an energy-sensing pathway is the phosphorylation of AMPKa by PKA at Ser-173. This site is highly conserved and located directly adjacent to the critical activation loop Thr-172, whose phosphorylation is absolutely required for AMPK activation (Carling et al, 2008) . Therefore, phosphorylation at Ser-173 may create constraints by steric hindrance or charge that are incompatible with subsequent phosphorylation at the adjacent Thr-172 residue. As such, this mechanism provides a novel means of negative regulation of AMPK activity. The fact that we were able to detect PKA/AMPKa1 complexes as well as Ser-173-phosphorylated AMPKa species also in different human cancer cell lines implies a function of this regulatory mechanism beyond regulation in the context of adipocyte lipolysis.
The physiologic relevance of PKA-mediated phosphorylation of AMPKa at Ser-173 in response to lipolytic hormones derives from the observation that AMPKaÀ/À MEFs differentiated into adipocytes and engineered to re-express an AMPKa1 mutant species resistant to PKA phosphorylation (AMPKa1(S173C)) released significantly less glycerol than cells expressing wild-type AMPKa1. These results suggest that PKA-mediated phosphorylation of AMPKa1 at Ser-173 represents a critical and relevant mechanism contributing to the regulation of lipolysis in vivo and that previously identified mechanisms such as the direct phosphorylation of the AMPK upstream kinases LKB1 or Ca 2 þ /Calmodulin-dependent kinase kinase 2 by PKA (Collins et al, 2000; Sapkota et al, 2001) or the direct phosphorylation of AMPKa1 at Ser-485/497 (Hurley et al, 2006) cannot fully account for the observed effects reported here. In addition, the results also support the view that regulation of lipolysis necessitates a balancing of the activities of PKA and AMPK in a coordinate manner such that PKA-stimulated lipolysis is followed by the activation of AMPK, which acts as part of a negative feedback that dampens again the rate of lipolysis. According to our model (Figure 8 ), PKA activation promotes efficient mobilization of TAG, at least in part, by opposing the activity of the AMPK-mediated negative feedback loop through phosphorylation of AMPKa at Ser-173. This leads to an increased output of the PKA-stimulated lipolytic pathway and finetuning of the lipolytic response, at least in the short term. However, in the longer term, AMPK activity ultimately rises to establish negative feedback inhibition of lipolysis to maintain adipocyte function. Therefore, it is conceivable that in this setting, AMPK safeguards against further depletion of ATP as a result of increased rates of NEFA reesterification. Notably, there is evidence to suggest that the rate of NEFA reesterification increases proportionally with the rate of lipolysis (Reshef et al, 1970; Brooks et al, 1982) .
Existing evidence suggests that in adipocytes, cAMP-PKA pathway activating signals such as isoproterenol, adrenaline or forskolin (Moule and Denton, 1998; Yin et al, 2003; Daval et al, 2005; Koh et al, 2007; Lobo et al, 2009; Omar et al, 2009) or exercise (Koh et al, 2007) induce AMPK activation within 30 min after application of the stimulus. On the basis of the response time and overexpression studies using a dominantinhibitory mutant of AMPKa2 (Yin et al, 2003) or pharmacological inhibition of AMPK by Compound C (Koh et al, 2007) , it has been proposed that AMPK stimulates lipolysis. However, a series of papers using a variety of cell systems (e.g. adipocytes derived from AMPKa1 knock-out mice) and approaches (e.g. shRNA-mediated knockdown of endogenous proteins) suggest that AMPK has anti-lipolytic activity (Daval et al, 2005; Gauthier et al, 2008; Lobo et al, 2009; Omar et al, 2009) , consistent with earlier in vivo studies showing an antilipolytic effect of the AMPK activator AICAR (Bergeron et al, 2001 ). In addition, these studies provide evidence that ongoing lipolysis is critical for the activation of AMPK in response to PKA-activating signals and that activation of AMPK occurs within 15-30 min after treatment of cells with agents that activate PKA (Moule and Denton, 1998; Yin et response to PKA stimulation is, however, not mutually exclusive with a model in which PKA inhibits AMPK in the short term, since PKA activation, respectively, PKA-mediated HSL phosphorylation, has been shown to occur within seconds after treatment of adipocytes with activators of PKA signalling (Martin et al, 2009 ). This rapid activation of PKA after b-adrenergic stimulation is in agreement with the model proposed here that suggests an inhibitory action of PKA on AMPK to promote efficient lipolysis.
A mechanism that remains to be investigated relates to the observed downregulation of PKA activity to allow the rise of AMPK activity. One could envision the action of a specific phosphatase that removes the Ser-173 inhibitory 5) . As control, cells were cultivated without orlistat but in the presence of 200 nM isoproterenol for 150 and 180 min in a serum-free DMEM and presence of glucose (lanes 6-8). Equal amounts of protein lysates were subjected to immunoblotting with the indicated antibodies. (D) Incubation medium of primary adipocytes described in (C) were processed for NEFA measurements. Bars represent the mean NEFA release from three independent experiments. (E) Primary adipocytes were treated with 10 mM triacsin C for 180 min and incubated with 200 nM isoproterenol for indicated times, in a serum-free DMEM and in the presence of glucose. Like in (C), isoproterenol was either present ab initio (lane 5), added during the last 30, 60 or 150 min of treatment (lanes 1-5). As control, cells were cultivated in the presence of 200 nM isoproterenol for 150 and 180 min in a serum-free DMEM and presence of glucose (lanes 6-8). Equal amounts of protein lysates were subjected to immunoblotting with the indicated antibodies. (F) Incubation medium of primary adipocytes described in (E) were processed for glycerol measurements as described in the Materials and methods section. Bars represent the mean NEFA or glycerol release from three independent experiments. Immunoblots are representative of at least three independent experiments. phosphorylation on AMPKa1, which in turn allows the phosphorylation and activation of AMPK by LKB1. Indeed, the phospho-Ser173 signal of AMPKa1 diminishes at later time points after isoproterenol treatment. As our anti-phospho Ser-173 antibody does not recognize phosphorylated Ser-173 when AMPKa1 is also phosphorylated at Thr-172 (see Figure 3A and B), we cannot formally exclude the possibility that Ser-173 remains phosphorylated despite increased phosphorylation of AMPKa1 at Thr-172. However, we also observed diminished phosphorylation of the PKA substrate CREB at the PKA-site Ser-133, suggesting that PKA activity has diminished at that time. Therefore, it is conceivable to hypothesize that also Ser-173 phosphorylation of AMPKa1 diminishes during this period of time after the addition of a lipolytic signal, pointing to the operation of a negative feedback mechanism that dampens PKA activity and thus contributes to the precise regulation of the lipolytic response.
In conclusion, our data provide insight into the mechanism of how information about systemic energy requirements is fed into decisions on the metabolic fate of lipids at the cellular level. Moreover, they suggest that this mechanism may have evolved to serve, in the first place, the energy requirements of the organism and not of the individual cell. As breakdown in the regulation of adipocyte lipid storage and mobilization pathways can contribute to increased levels of NEFAs in the circulation, which is an established risk factor for the development of insulin resistance in type II diabetes (Gesta et al, 2006; Guilherme et al, 2008) , it will be important to elucidate the regulation of the PKA-AMPK circuitry identified here in such disease settings. [g- 32 P]ATP was purchased from Hartmann Analytic (Braunschweig, Germany). l-PPase was obtained from New England Biolabs (Frankfurt, Germany). Tetrameric, partially purified cAMP-dependent protein kinase A holoenzyme (PKA[holo]) from bovine heart, myristoylated and non-myristoylated protein kinase A inhibitor fragment 5-24 (PKi), isoproterenol, H89 and forskolin, ionomycin, orlistat and free glycerol reagent were obtained from Sigma (St Louis, MO). Triacsin C was obtained from Biomol and rosiglitazone was obtained from Alexis Biochemicals. The SAMS peptide (HMRSAMSGLHLVKRR) was synthesized by EZBiolab (Westfield, IN). All other chemicals and reagents were from standard suppliers. U2-OS and HepG2 cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, MA). Predesigned and validated small interfering RNA (siRNA) for LKB1 gene silencing (#1498210 HP) was from Qiagen (Valencia, CA). Two different sets of siRNA for co-silencing of the a-and b-subunit of PKA were synthesized by Qiagen to target the following sequences: siRNA PKAset 1 (PKAa: ACAGAAGGTGGTGAAACTGAA, PKAb: GGCATTAG GAGTGCTAATCTA), siRNA PKA -set 2 (PKAa: CAGTGTGCTGTTG TAAACATA, PKAb: ACCAATGTGTTCTATATGTAA).
Materials and methods
Materials
Antibodies
Custom-made anti-phospho-Ser-173 and anti-phospho-Ser-497 AMPKa1 antibodies were from Eurogentec (Seraing, Belgium). Antibodies were raised in rabbits against keyhole limpet hemocyanin-coupled peptides H 2 N-GEFLRTS(PO 3 H 2 )CGSPNY-CONH 2 and H 2 N-CQRSDS(PO 3 H 2 )DAEAQGK-CONH 2 , followed by double-affinity purification on appropriate non-phosphopeptide-and phosphopeptide-coupled columns. Sheep anti-AMPKa1 and sheep antiAMPKg1 antibodies were a kind gift from DG Hardie (Dundee University, UK). Anti-ACC, anti-phospho-Ser-79 ACC, anti-AMPKa1, anti-phospho-Thr-172 AMPK, anti-phospho-Ser-485 AMPK, antiphospho-Ser-563 HSL, anti-phospho-Ser-565 and anti-phospho-Ser-660 HSL antibodies were obtained from Cell Signaling Technology (Beverly, CA). Anti-HSL was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CREB and anti-phospho-Ser-133-CREB were obtained from Abcam.
Plasmids
The plasmid for expression of the hexahistidine-tagged catalytic domain of PKA (PKA[cat]) in bacteria was a kind gift of RKY Cheng and LN Johnson (Oxford, UK). GST-HSL plasmid was a gift from R Ricci (ETH Zurich, Switzerland). Tricistronic plasmids encoding all three subunits of AMPK were constructed as described elsewhere Woods et al, 2003) . Mutations encoding for single amino acid changes were introduced into the a1-and b1-subunits of AMPKa1 using the QuikChange mutagenesis procedure (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Primer sequences and cloning details are available from authors on request.
Recombinant protein expression
The hexahistidine-tagged catalytic domain of PKA was purified by immobilized-metal affinity chromatography using 1 ml His-Trap FF crude columns (GE Healthcare, Otelfingen, Switzerland) according to the manufacturer's instructions. Recombinant LKB1 was expressed and purified as described earlier (Neumann et al, 2007) . Expression of recombinant AMPK in Escherichia coli was performed overnight at room temperature in 1 l of auto-inducing medium as described (Studier, 2005) . Proteins were purified by Ni-NTA chromatography and gel filtration as published earlier . 
Infection of adipocytes with adenoviruses
Adenoviruses were propagated in human embryonic kidney 293 cells and stored at À801C. Adipocytes were infected directly in their culture DMEM medium containing, 5% fetal calf serum, 2% BSA and antibiotics. The efficiency of infection was estimated by the presence of green fluorescent protein in adipocytes, produced from an independent promoter. Adipocytes were infected for a maximum of 48 h before immunoblotting experiments and lipolysis assays.
Immunoblotting and immunoprecipitation
Primary adipocytes from a 6 cm-culture dish were washed once in ice-cold phosphate-buffered saline and lysed in 300 ml of RIPA buffer (10 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton-X 100, 10% (v/v) glycerol), supplemented with protease inhibitors and processed for immunoblotting and immunoprecipitation as described (Djouder et al, 2007) .
ATP measurement
ATP was measured using an ATP bioluminescence assay kit ApoSENSOR TM (MBL) and a TD20/20 luminometer (Turner Designs).
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
